Publications by authors named "Yvonne Voges"
Article Synopsis
- Survivin is a drug target, and the drug candidate YM155 has shown promise for treating high-risk neuroblastoma, but some cancer cells can develop resistance to it.
- In a study of YM155-adapted UKF-NB-3 sublines, researchers found that increased ABCB1 levels and decreased SLC35F2 levels were linked to YM155 resistance, but these indicators did not predict sensitivity to YM155 in untreated cells.
- The resistant sublines displayed high heterogeneity and varied responses to other anti-cancer drugs, suggesting that cancer treatment needs to be personalized and that monitoring cell evolution and resistance indicators is essential.
The survivin suppressant YM155 is a drug candidate for neuroblastoma. Here, we tested YM155 in 101 neuroblastoma cell lines (19 parental cell lines, 82 drug-adapted sublines). Seventy seven (77) cell lines displayed YM155 ICs in the range of clinical YM155 concentrations.
View Article and Find Full Text PDFNickel metal is a naturally occurring element used in many industrial and consumer applications. Human epidemiological data and animal cancer bioassays indicate that nickel metal is not likely to be a human carcinogen. Yet, nickel metal is classified as a suspected human carcinogen (CLP) and possibly carcinogenic to humans (IARC).
View Article and Find Full Text PDFArticle Synopsis
- Resistance formation is common in high-risk neuroblastoma patients after initial therapy, leading to the investigation of YM155, a drug initially thought to target survivin, but now believed to also induce DNA damage and deplete Mcl-1.
- In studies of neuroblastoma cells resistant to other drugs, YM155 was found to inhibit cell viability by reducing survivin levels and activating p53, especially when combined with MDM2 inhibitors.
- The research highlights that adaptations in cancer cells, including changes in ABCB1 and SLC35F2 levels and mutations in p53, can lead to resistance against YM155, suggesting survivin remains a critical therapeutic target for p53 wild-type neuroblastomas in future treatments.
The CDK inhibitor SNS-032 had previously exerted promising anti-neuroblastoma activity via CDK7 and 9 inhibition. ABCB1 expression was identified as major determinant of SNS-032 resistance. Here, we investigated the role of ABCB1 in acquired SNS-032 resistance.
View Article and Find Full Text PDFFlubendazole was shown to exert anti-leukaemia and anti-myeloma activity through inhibition of microtubule function. Here, flubendazole was tested for its effects on the viability of in total 461 cancer cell lines. Neuroblastoma was identified as highly flubendazole-sensitive cancer entity in a screen of 321 cell lines from 26 cancer entities.
View Article and Find Full Text PDFArticle Synopsis
- Novel treatment strategies are needed for high-risk neuroblastoma, and the study focused on SNS-032, a CDK inhibitor, tested on 109 neuroblastoma cell lines, revealing significant anti-cancer effects.
- Approximately 73% of cell lines showed a reduction in cell viability by 50% at therapeutic levels of SNS-032, while 62% achieved a 90% reduction.
- The mechanism of action involved inhibiting CDK7 and CDK9, leading to decreased RNA synthesis and reduction of antiapoptotic proteins, suggesting SNS-032 as a potential treatment for neuroblastoma, including cases resistant to other therapies.